Leslie, W. D.
Majumdar, S. R.
Morin, S. N.
Lix, L. M.
Schousboe, J. T.
Ensrud, K. E.
Johansson, H.
McCloskey, E. V.
Kanis, J. A.
Article History
Received: 1 December 2017
Accepted: 24 January 2018
First Online: 5 February 2018
Compliance with ethical standards
: The study was approved by the Health Research Ethics Board for the University of Manitoba.
: Suzanne Morin: Research Grants: Amgen, Merck.Eugene McCloskey: Nothing to declare for FRAX and the context of this paper, but numerous ad hoc consultancies/speaking honoraria and/or research funding from Amgen, Bayer, General Electric, GSK, Hologic, Lilly, Merck Research Labs, Novartis, Novo Nordisk, Nycomed, Ono, Pfizer, ProStrakan, Roche, Sanofi-Aventis, Servier, Tethys, UBS, and Warner-Chilcott.John A. Kanis: Grants from Amgen, grants from Lilly, non-financial support from Medimaps, grants from Unigene, non-financial support from Asahi, and grants from Radius Health, outside the submitted work. Dr. Kanis is the architect of FRAX but has no financial interest. Governmental and NGOs: National Institute for health and clinical Excellence (NICE), UK; International Osteoporosis Foundation; INSERM, France; Ministry of Public Health, China; Ministry of Health, Australia; Ministry of Health, Abu Dhabi; National Osteoporosis Guideline Group, UK; WHO.William Leslie, Sumit Majumdar, Lisa Lix, H. Johansson, John T. Schousboe, Kristine E. Ensrud: None.